Literature DB >> 27027798

Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.

Haitao Wang1,2, Carter Lindborg1,2, Vitali Lounev1,2, Jung-Hoon Kim3, Ruth McCarrick-Walmsley1,2, Meiqi Xu1,2, Laura Mangiavini4, Jay C Groppe5, Eileen M Shore1,2,6, Ernestina Schipani4, Frederick S Kaplan1,2,3, Robert J Pignolo1,2,3.   

Abstract

Hypoxia and inflammation are implicated in the episodic induction of heterotopic endochondral ossification (HEO); however, the molecular mechanisms are unknown. HIF-1α integrates the cellular response to both hypoxia and inflammation and is a prime candidate for regulating HEO. We investigated the role of hypoxia and HIF-1α in fibrodysplasia ossificans progressiva (FOP), the most catastrophic form of HEO in humans. We found that HIF-1α increases the intensity and duration of canonical bone morphogenetic protein (BMP) signaling through Rabaptin 5 (RABEP1)-mediated retention of Activin A receptor, type I (ACVR1), a BMP receptor, in the endosomal compartment of hypoxic connective tissue progenitor cells from patients with FOP. We further show that early inflammatory FOP lesions in humans and in a mouse model are markedly hypoxic, and inhibition of HIF-1α by genetic or pharmacologic means restores canonical BMP signaling to normoxic levels in human FOP cells and profoundly reduces HEO in a constitutively active Acvr1(Q207D/+) mouse model of FOP. Thus, an inflammation and cellular oxygen-sensing mechanism that modulates intracellular retention of a mutant BMP receptor determines, in part, its pathologic activity in FOP. Our study provides critical insight into a previously unrecognized role of HIF-1α in the hypoxic amplification of BMP signaling and in the episodic induction of HEO in FOP and further identifies HIF-1α as a therapeutic target for FOP and perhaps nongenetic forms of HEO.
© 2016 American Society for Bone and Mineral Research. © 2016 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CELL/TISSUE SIGNALING; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; PRECLINICAL STUDIES

Mesh:

Substances:

Year:  2016        PMID: 27027798      PMCID: PMC5010462          DOI: 10.1002/jbmr.2848

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  77 in total

1.  Rab5 is necessary for the biogenesis of the endolysosomal system in vivo.

Authors:  Anja Zeigerer; Jerome Gilleron; Roman L Bogorad; Giovanni Marsico; Hidenori Nonaka; Sarah Seifert; Hila Epstein-Barash; Satya Kuchimanchi; Chang Geng Peng; Vera M Ruda; Perla Del Conte-Zerial; Jan G Hengstler; Yannis Kalaidzidis; Victor Koteliansky; Marino Zerial
Journal:  Nature       Date:  2012-05-23       Impact factor: 49.962

2.  A novel in vivo model to study endochondral bone formation; HIF-1alpha activation and BMP expression.

Authors:  Pieter J Emans; Frank Spaapen; Don A M Surtel; Keryn M Reilly; Andy Cremers; Lodewijk W van Rhijn; Sjoerd K Bulstra; Jan Willem Voncken; Roel Kuijer
Journal:  Bone       Date:  2006-09-18       Impact factor: 4.398

3.  Oxygen sensor boosts growth factor signaling.

Authors:  Mien-Chie Hung; Gordon B Mills; Dihua Yu
Journal:  Nat Med       Date:  2009-03       Impact factor: 53.440

4.  Hypoxia enhances the generation of induced pluripotent stem cells.

Authors:  Yoshinori Yoshida; Kazutoshi Takahashi; Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2009-08-27       Impact factor: 24.633

5.  Hypoxia, HIFs and bone development.

Authors:  Elisa Araldi; Ernestina Schipani
Journal:  Bone       Date:  2010-05-02       Impact factor: 4.398

6.  Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Authors:  Andria L Culbert; Salin A Chakkalakal; Edwin G Theosmy; Tracy A Brennan; Frederick S Kaplan; Eileen M Shore
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 7.  Endocytic regulation of TGF-beta signaling.

Authors:  Ye-Guang Chen
Journal:  Cell Res       Date:  2009-01       Impact factor: 25.617

8.  Regulation of endocytosis via the oxygen-sensing pathway.

Authors:  Yi Wang; Olga Roche; Mathew S Yan; Greg Finak; Andrew J Evans; Julie L Metcalf; Bridgid E Hast; Sara C Hanna; Bill Wondergem; Kyle A Furge; Meredith S Irwin; William Y Kim; Bin T Teh; Sergio Grinstein; Morag Park; Philip A Marsden; Michael Ohh
Journal:  Nat Med       Date:  2009-03-01       Impact factor: 53.440

9.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

10.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Authors:  Kathryn R Taylor; Alan Mackay; Nathalène Truffaux; Yaron Butterfield; Olena Morozova; Cathy Philippe; David Castel; Catherine S Grasso; Maria Vinci; Diana Carvalho; Angel M Carcaboso; Carmen de Torres; Ofelia Cruz; Jaume Mora; Natacha Entz-Werle; Wendy J Ingram; Michelle Monje; Darren Hargrave; Alex N Bullock; Stéphanie Puget; Stephen Yip; Chris Jones; Jacques Grill
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  40 in total

Review 1.  Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.

Authors:  Kelly L Wentworth; Umesh Masharani; Edward C Hsiao
Journal:  Br J Clin Pharmacol       Date:  2019-01-06       Impact factor: 4.335

2.  Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Robert J Pignolo; Mona M Al Mukaddam; Eileen M Shore
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-17       Impact factor: 0.694

3.  Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Kazuhiko Horigome; Megumi Nishio; Shingo Komura; Sanae Nagata; Chengzhu Zhao; Yonghui Jin; Koichi Kawakami; Yasuhiro Yamada; Akira Ohta; Junya Toguchida; Makoto Ikeya
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

4.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

Review 5.  Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.

Authors:  Koji Matsuo; Robert Dalton Chavez; Emilie Barruet; Edward C Hsiao
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

Review 6.  Conserved signaling pathways underlying heterotopic ossification.

Authors:  Chen Kan; Lijun Chen; Yangyang Hu; Na Ding; Haimei Lu; Yuyun Li; John A Kessler; Lixin Kan
Journal:  Bone       Date:  2017-04-25       Impact factor: 4.398

Review 7.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

8.  Injury of Adult Zebrafish Expressing Acvr1lQ204D Does Not Result in Heterotopic Ossification.

Authors:  Melissa LaBonty; Nicholas Pray; Pamela C Yelick
Journal:  Zebrafish       Date:  2018-09-05       Impact factor: 1.985

9.  Decreased inspired oxygen stimulates de novo formation of coronary collaterals in adult heart.

Authors:  Amir Aghajanian; Hua Zhang; Brian K Buckley; Erika S Wittchen; Willa Y Ma; James E Faber
Journal:  J Mol Cell Cardiol       Date:  2020-10-08       Impact factor: 5.000

10.  Muscle Tissue Damage and Recovery After EV71 Infection Correspond to Dynamic Macrophage Phenotypes.

Authors:  Mei-Yi Lu; Ya-Lin Lin; Yali Kuo; Chi-Fen Chuang; Jen-Ren Wang; Fang Liao
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.